Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade

Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade

Prognosis of glioblastoma remains dismal, underscoring the need for novel therapies. Immunotherapy is generating promising results, but requires combination strategies to unlock its full potential. We investigated the immunomodulatory capacities of poly(I:C) on primary human glioblastoma cells and i...

Full description

Bibliographic Details
Main Authors: Jorrit De Waele, Elly Marcq, Jonas RM Van Audenaerde, Jinthe Van Loenhout, Christophe Deben, Karen Zwaenepoel, Erik Van de Kelft, David Van der Planken, Tomas Menovsky, Johan MJ Van den Bergh, Yannick Willemen, Patrick Pauwels, Zwi N Berneman, Filip Lardon, Marc Peeters, An Wouters, Evelien LJ Smits
Format: Article
Language:English
Published: Taylor & Francis Group 2018-03-01
Series:OncoImmunology
Subjects:
glioblastoma (gbm)
poly(i:c)
toll-like receptor 3 (tlr3)
cancer immunotherapy
programmed death ligand 1 (pd-l1)
programmed death ligand 2 (pd-l2)
immune checkpoint blockade
primary patient-derived cells
brain tumor
glioma
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1407899

Internet

http://dx.doi.org/10.1080/2162402X.2017.1407899

Similar Items